4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection
|
|
- Ellen Burns
- 5 years ago
- Views:
Transcription
1 ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1
2 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic Pfizer Corporation Austria Ges.m.b.H Floridsdorfer Hauptstraße 1, A-1210 Wien Austria Pfizer S.A. Boulevard de la Plaine Brussels Pfizer S.A. Boulevard de la Plaine Brussels Pfizer Hellas A.E. 243 Messoghion Avenue Neo Psychico Pfizer Hellas A.E. 243 Messoghion Avenue Neo Psychico Pfizer spol. s r.o. Stroupežnického 3191/17, Praha Smíchov, Czech Republic Tazonam 4,0 g/0,5 g - Trockenstechampullen 2g/250 mg poudre pour solution injectable 4g/500 mg poudre pour solution injectable (TAZOCIN 4 g/0,5 g powder for solution for / Piperacillin/Tazobactam) TAZOCIN EF TAZOCIN EF 2,25 g 4,0 g/0,5 g 2g/250 mg 4 g/500 mg 4g/0,5g 2.25 G/VIAL 4.5 G/VIAL 2,25 g Lyophilisate for solution for or powder for solution for / use use use 1 vial contains piperacillin sodium equivalent to 4.0g of piperacillin and sodium equivalent to 0.5g of. 2,085 g sodium piperacillin + 268,30 mg sodium 4,170 g sodium piperacillin + 536,60 mg sodium g piperacillin sodium equivalent to 4 g equivalent to 500 milligrams g sodium piperacillin equivalent to 2 g piperacillin and g sodium equivalent to g g sodium piperacillin equivalent to 4 g piperacillin and g sodium equivalent to 0.5 g. 2 g piperacillinum / 0,25 g um 2
3 Czech Republic Denmark Denmark Estonia Finland Finland France Pfizer spol. s r.o. Stroupežnického 3191/17, Praha Smíchov Czech Republic Pfizer ApS Lautrupvang Ballerup Denmark Pfizer ApS Lautrupvang Ballerup Denmark Pfizer Oy Tietokuja 4, Helsinki, Finland Pfizer Oy Tietokuja 4, Helsinki, Finland Pfizer, Coeur Défense - Tour A La Défense PARIS LA DEFENSE Cedex France 4,5 g TAZOCIN 4,5G 4,5 g 2 g/0,25 g 4 g/0,5 g 4000m g+500mg g 2 g/0,25 g 4 g/0,5 g TAZOCILLINE 2 g/250 mg, poudre pour solution 2g/250mg pour perfusion / / or / / use Infusion 4 g piperacillinum / 0,5 g um piperacillin 2 g, 0,25 g. piperacillin 4 g, 0,5 g 4,170 g piperacillin sodium equivalent to 4000 mg of equivalent to 500 mg of. Piperacillin. sodium g Tazobactam.sodium 0,2683 g Piperacillin. sodium g Tazobactam.sodium 0,5366 g Sodium piperacillin g sodium mg 3
4 France Germany Pfizer, Coeur Défense - Tour A La Défense PARIS LA DEFENSE Cedex France Pfizer Pharma GmbH Linkstr Berlin Germany TAZOCILLINE 4 g/500 mg, poudre pour solution 4g/500mg pour perfusion Tazobac EF 4g/0,5g 4g/0.5g Lyophilisate for or Infusion (Infusion, Injection) Sodium piperacillin g sodium mg 4 g piperacillin equivalent to 4.17 g piperacillin sodium 0.5 g equivalent to g sodium Hungary Pfizer Hellas A.E. 243 Messoghion Avenue Neo Psychico Pfizer Hellas A.E. 243 Messoghion Avenue Neo Psychico Wyeth Whitehall Export GmbH Storchengasse 1 A-1150 Vienna Austria TAZOCIN EF TAZOCIN EF 2+0,250 G/VIAL 4+0,500 G/VIAL 4,5 g injekció 4.5g or use use g sodium piperacillin equivalent to 2 g piperacillin and g sodium equivalent to g g sodium piperacillin equivalent to 4 g piperacillin and g sodium equivalent to 0.5 g g sodium equivalent to g and g piperacillin sodium equivalent to 4.00 g piperacillin 4
5 Ireland Ireland Italy Italy Latvia John Wyeth & Brother Limited Taplow, Maidenhead, Berks, SL6 0PH John Wyeth & Brother Limited Taplow, Maidenhead, Berks, SL6 0PH Wyeth Lederle S.p.A. Via Nettunense, 90 Aprilia (LT), 04011, Italy Wyeth Lederle S.p.A. Via Nettunense, 90 Aprilia (LT), 04011, Italy 2g/0.25g Powder for Solution for Injection or Infusion 4g/0.5g Powder for Solution for Injection or Infusion TAZOCIN TAZOCIN TAZOCIN 4,0g/0,5g pulveris injekciju vai infūziju šķīduma pagatavošanai 2g/0.25g 4g/0.5g 2g+0,250g 4g g 4,0g/0,500 mg or use use 2g piperacillin and 0.25g (both present as sodium salts). 4g piperacillin and 0.5g (both present as sodium salts). (equiv. to piperacillin 2g) 2085 mg Tazobactam sodium (equiv. to 250 mg) 268,3 mg (equiv. to piperacillin 4 g) 4170 mg Tazobactam sodium (equiv. to 500 mg) 536,6 mg g piperacillin sodium equivalent to 4g equivalent to 500 milligrams 5
6 Lithuania Luxembourg Luxembourg Malta Malta Netherlands Pfizer S.A. Boulevard de la Plaine Brussels Pfizer S.A. Boulevard de la Plaine Brussels John Wyeth & Brother Limited Taplow Maidenhead Berkshire SL6 0PH John Wyeth & Brother Limited Taplow Maidenhead Berkshire SL6 0PH Pfizer B.V. Rivium westlaan LD Capelle a/d IJssel The Netherlands TAZOCIN 2g/250 mg poudre pour solution injectable 4g/500 mg poudre pour solution injectable 2g/0.25 g TAZOCIN 4g/0.5g 2 g/ 250 mg 4,0g/0,5g 2g/250 mg 4g/500 mg 2g/0.25g 4g/0.5g 2g /250 mg or g piperacillin sodium equivalent to 4g equivalent to 500 milligrams 2,085 g sodium piperacillin + 268,30 mg sodium 4,170 g sodium piperacillin + 536,60 mg sodium TAZOCIN 2g/0.25g contains 2 active ingredients; piperacillin 2g and 0.25g both present as sodium salts. TAZOCIN 4g/0.5g contains 2 active ingredients; piperacillin 4g and 0.5g both present as sodium salts. Sodium piperacillin and sodium, equivalent to 2 g piperacillin and 250 mg. 6
7 Netherlands Norway Norway Poland Poland Portugal Pfizer B.V. Rivium westlaan LD Capelle a/d IJssel The Netherlands Pfizer AS Postboks Lysaker Norway Pfizer AS Postboks Lysaker Norway Instituto Pasteur de Lisboa, S.A. Rua Dr. António Loureiro Borges, 2 Arquiparque - Miraflores ALGÉS Portugal 4 g/ 500 mg 4 g/500mg 2 g/0,25 g 4 g/0,5 g 2g + 0,25g 4g + 0,5g Tazobac 2000mg mg / / or or use Sodium piperacillin and sodium, equivalent to 4 g piperacillin and 500 mg piperacillin 2 g,. 0,25 g piperacillin 4 g, 0,5 g. 2 g piperacillin (in form of piperacillin sodium) and 0,25 g (in form of sodium). 4 g piperacillin (in form of piperacillin sodium) and 0,5 g (in form of sodium) g of piperacillin sodium equivalent to 2 g of piperacillin and g of equivalent to 250 mg of 7
8 Portugal Romania Romania Slovak Republic Slovak Republic Slovenia Instituto Pasteur de Lisboa, S.A. Rua Dr. António Loureiro Borges, 2 Arquiparque - Miraflores ALGÉS Portugal Tazobac 2,25 g, liofilizat pentru soluţie injectabilă/ perfuzabilă 4,5 g, liofilizat pentru soluţie injectabilă/ perfuzabilă 4000mg mg 2,00/0,25g 4,00/0,5g 2,25g 2.25g 4,5g 4.5g TAZOCIN 4,5 g prašek za raztopino za injiciranje ali infundiranje 4.0g/0.5g Lyophilised powder for solution for or Lyophilised powder for solution for or and and or. use g of piperacillin sodium equivalent to 4 g of of equivalent to 500 mg of Piperacillin 2.00 g as piperacillin sodium and 0.25 g as sodium. Piperacillin 4.00 g as piperacillin sodium and 0.5 g as sodium. contains 2.085g piperacillin sodium equivalent to 2g piperacillin and g equivalent to 250 milligrams contains g piperacillin sodium equivalent to 4g equivalent to 500 milligrams g piperacillin sodium equivalent to 4 g sodium equivalent to 500 mg. 8
9 Spain Spain Sweden Sweden Wyeth Farma S.A. Ctra. Burgos, Km 23 - Desvío Tazocel 2/0,25 g Algete Km 1 Polvo para San Sebastián de los solución Reyes (Madrid) inyectable Spain Wyeth Farma S.A. Ctra. Burgos, Km 23 - Desvío Tazocel 4/0,5 g Algete Km 1 Polvo para San Sebastián de los solución Reyes (Madrid), inyectable Spain Pfizer AB Vetenskapsvägen Sollentuna, Sweden Pfizer AB Vetenskapsvägen Sollentuna, Sweden John Wyeth & Brother Limited Taplow Maidenhead Berkshire SL6 0PH TAZOCIN 2g/0.25g 2/0,25 g 4/0,5 g 2 g/0,25 g 4 g/0,5 g 2.25g Powder for injectable solution Powder for injectable solution / / Piperacillin (in the form of piperacillin sodium) 2 g Tazobactam (in the form of ) 0.25 g Piperacillin (in the form of piperacillin sodium) 4 g Tazobactam (in the form of ) 0.50 g piperacillin 2 g and 0,25 g piperacillin 4 g and 0,5 g Piperacillin 2g and 250mg both present as sodium salts. 9
10 Route of ) John Wyeth & Brother Limited Taplow Maidenhead Berkshire SL6 0PH TAZOCIN 4g/0.5g 4.5g Piperacillin 4g and 500mg both present as sodium salts. 10
4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection
ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Marketing Authorisation
More informationMember State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationSortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Austria Austria
More information(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria
More information(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More information(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium
More informationPARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information
PARALLELISM AND THE LEGITIMACY GAP 1 Appendix A Country Information PARALLELISM AND THE LEGITIMACY GAP 2 Table A.1 Sample size by country 2006 2008 2010 Austria 2405 2255 0 Belgium 1798 1760 1704 Bulgaria
More informationMember State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation
More informationTadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan
More informationLEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
More information(Invented) Name Strength Pharmaceutical form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria Austria Austria
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Brussels, 17.6.011 COM(011) 35 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationINN Product name Strength Pharmaceutical form
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation (s) in the member states 1 Targin 10 mg/5 mg prolongedrelease Targin 20 mg/10
More informationAmoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of applicant/marketing authorisation holder in the member states 1/10 Member State EU/EEA
More informationEuropean Collaboration on Dementia. Luxembourg, 13 December 2006
European Collaboration on Dementia Luxembourg, 13 December 2006 2005 Call for projects Special attention has also to be given to information and definition of indicators on neurodegenerative, neurodevelopment,
More informationGERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
More informationMonthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
More informationRheumatoid Arthritis Disease Burden and Access to Treatment
Berlin, April 2012 Rheumatoid Arthritis Disease Burden and Access to Treatment Gisela Kobelt, PhD Visiting Professor, Lund University (Sweden) President, European Health Economics (France) Disclaimers
More informationWhere we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
More informationTEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée
Teddy Network of Excellence Annagrazia ALTAVILLA TEDDY Task-force in Europe for Drug Development for the Young Ph.D. Sciences Ethics LL.M. Health Law Associated Senior Lecturer Université de la MéditerranM
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. InductOs 12 mg kit for implant dibotermin alfa
PACKAGE LEAFLET: INFORMATION FOR THE USER InductOs 12 mg kit for implant dibotermin alfa Read all of this leaflet carefully before you are given this medicine. Keep this leaflet. You may need to read it
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationGlobal Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd (www.tradedata.net) Page 1 5/18/2015
Page 1 5/18/2015 An Analysis of Global Trade in Lightweight paper, coated with inorganic substances, used for writing etc., of which more than 10% by weight of total fibre content consists of fibres obtained
More informationYersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Yersiniosis Key facts In 2015, 26 countries reported 7 279 confirmed yersiniosis cases in the EU/EEA. The overall notification rate was 2.0 cases
More informationPiperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam
Package leaflet : Information for the user Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam Read all of this leaflet carefully before you start
More informationEngagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
More informationResearch paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union
Parliament of Montenegro Parliamentary Institute Research Centre Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union Podgorica, December
More informationNutrient profiles for foods bearing claims
Nutrient profiles for foods bearing claims Fields marked with * are mandatory. Background Regulation (EC) 1924/2006 (Nutrition and Health Claims NHC Regulation) establishes EU rules on nutrition and health
More informationQ1 What age are you?
Q1 What age are you? Answered: 504 Skipped: 0 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 4.56% 23 3.77% 19 4.56% 23 6.15% 31 3.97% 20 6.55% 33 5.95% 30 6.75% 34 6.35% 32 4.37% 22 6.75% 34 5.56%
More informationreal-time AQ data 2007 and plans for 2008
real-time AQ data 2007 and plans for 2008 Tim Haigh - project manager Information Resources http://www.eea.europa.eu/maps/ozone/map/ Where is all the data coming from? EEA NRT Database 4000 2000 700 EEA
More informationOutcome of proficiency test on EIA serology
Outcome of proficiency test on EIA serology Anses Dozulé Laboratory for equine diseases VIPARE unit Delphine Gaudaire EIA PT GENERAL INFORMATION AIM OF THE PT Detect EIA antibodies: using Agar Gel Immuno-Diffusion
More informationPackage leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride
Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using
More informationThe cancer burden in the European Union and the European Region: the current situation and a way forward
The cancer burden in the European Union and the European Region: the current situation and a way forward Presented by Zsuzsanna Jakab WHO Regional Director for Europe Informal Meeting of Health Ministers
More informationMedia Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences
Media Release Embargoed 00.01 CET Monday 12 th March 2012 Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences Up to 70 percent of
More informationEuropean Community Pharmacy: a reference in Public Health
European Community Pharmacy: a reference in Public Health Ilaria Passarani PGEU Secretary General 4 October 2018, Burgos, Spain Pharmaceutical Group of European Union Members: Professional Bodies & Pharmacists
More informationInjecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration
Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration Alexander Grabenhofer-Eggerth TDI expert meeting - Lisbon,
More informationThe Risk of Alcohol in Europe. Bridging the Gap June 2004
The Risk of Alcohol in Europe Bridging the Gap 16-19 June 2004 1. What is the relationship between alcohol and the risk of heart disease? 2. What is the relationship between alcohol and the risk of other
More informationPUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 15 June 1999 EMEA/18046/99 PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)
More informationAnimal species. Member State EU/EEA. Route of administration. Strength. Applicant Name INN Pharmaceutical form. Austria 1
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of administration, applicant in the Member States 1 Member State EU/EEA Applicant Name
More informationDrinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results
Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results E. Scafato, C. Gandin, L. Galluzzo, S. Ghirini, S. Martire Istituto Superiore
More informationMEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne
MEDICINES SHORTAGES John Chave - Secretary general Members: Professional Bodies & Pharmacists Associations 2013: 32 Countries Austria Belgium Bulgaria Bosnia Herzegovina Cyprus Czech Rep Denmark Estonia
More informationAlcohol-related harm in Europe and the WHO policy response
Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related
More informationAtherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke
«L Europe de la santé au service des patients» 13-14 October 2008 - Institut Pasteur Paris Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke Simona Giampaoli National Centre of
More informationUnderage drinking in Europe
Underage drinking in Europe There are two major studies on underage drinking which are published every 4 years: HBSC (Health Behaviour in School-aged Children) and ESPAD (The European School survey Project
More informationEmerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018
Emerging Risks Mapping of Activities in Member States 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018 BACKGROUND 67 th Advisory Forum Meeting, Utrecht, The Netherlands, 6 February
More informationBiology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium
More informationPRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY
PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY EMBARGOED FOR RELEASE AT 6:00A.M. EST, FEBRUARY 20, 2001. NOTE TO EDITORS These results will be presented today (Tuesday, February 20,
More informationReal Life, Real PD Survey
Real Life, Real PD Survey Final Pan-European Survey Results Survey Objectives The survey was carried out to provide insights into the realities of living with PD and to highlight some of the symptoms of
More informationMember State Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation
More informationALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY
ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY JACEK MOSKALEWICZ INSTITUTE OF PSCHIATRY AND NEUROLOGY WARSAW, POLAND THIRD EUROPEAN CONFERENCE ON ALCOHOL AND LAW ENFORCEMENT,
More informationMarketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Austria Austria Austria
More informationUK bowel cancer care outcomes: A comparison with Europe
UK bowel cancer care outcomes: A comparison with Europe What is bowel cancer? Bowel cancer, which is also known as colorectal or colon cancer, is a cancer that affects either the colon or the rectum. The
More informationAnnex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
More informationWhere do EU Contries set the limit for low risk drinking.
Where do EU Contries set the limit for low risk drinking. Results from the EU RARHA survey E. Scafato,L. Galluzzo, S. Ghirini, C. Gandin Istituto Superiore di Sanità, Italy WP5: Outline of the work (tasks)
More informationFoodstuffs - Determination of vitamin D by high performance liquid chromatography - Measurement of cholecalciferol (D3) or ergocalciferol (D2)
Irish Standard Foodstuffs - Determination of vitamin D by high performance liquid chromatography - Measurement of cholecalciferol (D3) or ergocalciferol (D2) NSAI 2009 No copying without NSAI permission
More informationEuropean Partnership for Screening
European Partnership for Screening Lawrence von Karsa Quality Assurance Group European Cancer Network for Screening and Prevention International Agency for Research on Cancer Lyon, France Work Package
More informationPackage leaflet: Information for the patient. Avodart 0.5 mg soft capsules dutasteride
Package leaflet: Information for the patient Avodart 0.5 mg soft capsules dutasteride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Sterofundin ISO solution for infusion
Package leaflet: Information for the user solution for infusion Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet.
More informationManuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal Public Health Public health is the science and art of preventing disease, prolonging
More informationIdentifying Europe s information needs for effective drug policy Lisbon, EMCCDA
Cannabis Market in Europe: A Growing Domestic Market (First Results) Jean-Michel Costes, Christian Ben Lakhdar OFDT 3 avenue du Stade de France 93218 Saint-Denis La Plaine cedex Tel : 01 41 62 77 16 Fax
More informationTrichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
Annual Epidemiological Report for 2015 Trichinellosis Key facts In 2015, a total of 156 confirmed cases of trichinellosis was reported from 29 EU/EEA countries. The overall notification rate was 0.03 cases
More informationNational Institute on Alcohol Abuse and Alcoholism. Environmental Approaches
Environmental Approaches Consumption of 10+ and 21+ Drinks on an Occasion At Least Once in the Past Year, 2013 30 25 20 15 10+ drinks 15 25 10+ drinks 16 25 10 5 0 21+ drinks 3 2 21+ drinks 18-20 21-24
More informationProject Meeting Prague
Project Meeting Prague IO1 Assessment 9.11.217 CHRISTINA PADBERG ON BEHALF OF FRANKFURT UAS Current Status Assessment matrix was fully evaluated Experts have been interviewed, Interviews were fully evaluated
More information31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million
31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites
More informationScreening for Cervical Cancer in Europe
Asturias, 23 October, 2011 Asturias, 23 October Screening for Cervical Cancer in Europe M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus,
More informationAnnex I. List of the names, pharmaceutical forms, strength of the medicinal product, route of administration, applicant in the Member States
Annex I List of the names, pharmaceutical forms, strength of the medicinal product, route of administration, applicant in the Member States 1 Member State EU/EEA Applicant Name Strength Pharmaceutic al
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationThe health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
More informationPlease note that this draft Annex I will be updated to amend information on concerned products/mahs
22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3
More informationInequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
More informationPackage leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate
Package leaflet: Information for the patient Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate Read all of this leaflet carefully before you are given this medicine because
More informationExtrapolation and potential impact of IPHS deployment in Europe
SIMPHS2 Validation Workshop Brussels, 31 Jan 2012 1 SIMPHS2 Validation Workshop Extrapolation and potential impact of IPHS deployment in Europe JRC IPTS IS Unit Ioannis Maghiros, Fabienne Abadie, Maria
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR 2012
EUROPEAN COMMISSION Brussels, 4.2.2014 COM(2014) 52 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR 2012 EN
More informationDepartment of Biological Standardisation OMCL Network & Healthcare (DBO)
Department of Biological Standardisation OMCL Network & Healthcare (DBO) Implementation of Pathogen Reduction Technologies for Blood Components for Transfusion: Updated Table 2009-2010 COUNCIL OF EUROPE
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Technescan MIBI 1 mg, kit for radiopharmaceutical preparation
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Technescan MIBI 1 mg, kit for radiopharmaceutical preparation [Tetrakis(2-methoxy-2-methylpropyl-1 isocyanide)copper(i)] tetrafluoroborate Read all of this
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD AND FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR 2015
EUROPEAN COMMISSION Brussels, 25.11.2016 COM(2016) 738 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD AND FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR
More informationMen & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013
Men & Health Promotion @ Work Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013 Difference can make a Difference Mens health: State of mens health Use of services Role of the
More informationPharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.
1 International International Conference on Harmonization (ICH) World Health Organization (WHO) 2 Argentina National Administration of Drugs, Food and medical Technology. Australia s Department of health
More information